Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis

Haematologica

Volumn 100, Issue 7, 2015, Pages e280-e284

  Bohers, Elodie ^a   Viailly, Pierre Julien ^a   Dubois, Sydney ^a   Bertrand, Philippe ^a   Maingonnat, Catherine ^a   Mareschal, Sylvain ^a   Ruminy, Philippe ^a   Picquenot, Jean Michel ^b   Bastard, Christian ^a   Desmots, Fabienne ^c   Fest, Thierry ^c   Leroy, Karen ^d   Tilly, Hervé ^a,b   Jardin, Fabrice ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b CENTRE HENRI BECQUEREL   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

Diffuse large B cell lymphoma; Liquid biopsy; Mutations; NGS

Indexed keywords

B LYMPHOCYTE RECEPTOR; CELL FREE CIRCULATING DNA; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; TUMOR PROTEIN;

APOPTOSIS; CELL CYCLE; DNA SEQUENCE; GENE EXPRESSION; HUMAN; IMMUNITY; LARGE CELL LYMPHOMA; LETTER; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE VARIANT; SOMATIC MUTATION; WHOLE EXOME SEQUENCING; ADOLESCENT; ADULT; AGED; B LYMPHOCYTE; CELL TRANSFORMATION; FEMALE; GENETICS; GERMINAL CENTER; HIGH THROUGHPUT SEQUENCING; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; FEMALE; GERMINAL CENTER; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS;

EID: 84936138377     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.123612     Document Type: Letter

References (15)

1. Morin RD, Gascoyne RD. Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. Semin Hematol. 2013;50(4):303-313.
2. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma- treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12-23.
3. Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579-586.
4. He J, Wu J, Jiao Y, et al. IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients. Oncotarget. 2011; 2(3):178-185.
5. Hosny G, Farahat N, Hainaut P. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. Cancer Lett. 2009;275(2):234-239.
6. Mussolin L, Burnelli R, Pillon M, et al. Plasma cell-free DNA in paediatric lymphomas. J Cancer. 2013;4(4):323-329.
7. Jones K, Nourse JP, Keane C, et al. Tumor-specific but not nonspecific cell-free circulating DNA can be used to monitor disease response in lymphoma. Am J Hematol. 2012;87(3):258-265.
8. Hohaus S, Giachelia M, Massini G, et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol. 2009; 20(8):1408-1413.
9. Bohers E, Mareschal S, Bouzelfen A, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2014;53(2):144-153.
10. Lanic H, Mareschal S, Mechken F, et al. Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(1):34-42.
11. Shuga J, Zeng Y, Novak R, et al. Single molecule quantitation and sequencing of rare translocations using microfluidic nested digital PCR. Nucleic Acids Res. 2013;41(16):e159.
12. Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013;163(1):123-126.
13. Logan AC, Vashi N, Faham M, et al. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014;20(9):1307-1313.
14. Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27(8):1659-1665.
15. Roschewski M, Dunleavy K, Pittaluga S, et al. Monitoring of circulating tumor DNA as minimal residual disease in diffuse large B-cell lymphoma. Blood. 2014;124(21):139 Abstr